188 related articles for article (PubMed ID: 25347711)
1. Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas.
Bantikassegn A; Song X; Politi K
Am J Respir Cell Mol Biol; 2015 Apr; 52(4):409-17. PubMed ID: 25347711
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.
Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J
Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908
[TBL] [Abstract][Full Text] [Related]
3. Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.
Wang DH; Lee HS; Yoon D; Berry G; Wheeler TM; Sugarbaker DJ; Kheradmand F; Engleman E; Burt BM
Clin Cancer Res; 2017 Feb; 23(3):778-788. PubMed ID: 27496865
[TBL] [Abstract][Full Text] [Related]
4. Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms.
Hegab AE; Ozaki M; Kagawa S; Hamamoto J; Yasuda H; Naoki K; Soejima K; Yin Y; Kinoshita T; Yaguchi T; Kawakami Y; Ornitz DM; Betsuyaku T
Lung Cancer; 2018 May; 119():25-35. PubMed ID: 29656749
[TBL] [Abstract][Full Text] [Related]
5. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
[TBL] [Abstract][Full Text] [Related]
6. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.
Sakuma Y
Pathol Int; 2017 Aug; 67(8):379-388. PubMed ID: 28678431
[TBL] [Abstract][Full Text] [Related]
8. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.
Lahtela J; Pradhan B; Närhi K; Hemmes A; Särkioja M; Kovanen PE; Brown A; Verschuren EW
Dis Model Mech; 2015 Apr; 8(4):393-401. PubMed ID: 25713296
[TBL] [Abstract][Full Text] [Related]
9. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Saruwatari K; Ikemura S; Sekihara K; Kuwata T; Fujii S; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ochiai A; Kohrogi H; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2016 Jan; 91():7-14. PubMed ID: 26711928
[TBL] [Abstract][Full Text] [Related]
10. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.
Calvayrac O; Pradines A; Raymond-Letron I; Rouquette I; Bousquet E; Lauwers-Cances V; Filleron T; Cadranel J; Beau-Faller M; Casanova A; Milia J; Favre G; Mazières J
Clin Cancer Res; 2014 Dec; 20(24):6541-50. PubMed ID: 25320360
[TBL] [Abstract][Full Text] [Related]
11. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
12. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Unni AM; Lockwood WW; Zejnullahu K; Lee-Lin SQ; Varmus H
Elife; 2015 Jun; 4():e06907. PubMed ID: 26047463
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification.
Shim HS; Lee DH; Park EJ; Kim SH
Arch Pathol Lab Med; 2011 Oct; 135(10):1329-34. PubMed ID: 21970488
[TBL] [Abstract][Full Text] [Related]
14. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.
Matsuo Y; Shiomi K; Sonoda D; Mikubo M; Naito M; Matsui Y; Yoshida T; Satoh Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):75-87. PubMed ID: 29090354
[TBL] [Abstract][Full Text] [Related]
16. Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.
Rau KM; Chen HK; Shiu LY; Chao TL; Lo YP; Wang CC; Lin MC; Huang CC
Int J Mol Sci; 2016 Apr; 17(4):524. PubMed ID: 27070580
[TBL] [Abstract][Full Text] [Related]
17. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
[TBL] [Abstract][Full Text] [Related]
18. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
20. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
